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1. Introduction  
Psoriasis, a chronic erythematosquamous dermatitis that affects about 2-3% of the 
population, is characterized by abnormal keratinocyte hyperproliferation, resulting in 
thickening of the epidermis and of the stratum corneum. Psoriasis vulgaris accounts for 90% 
of the psoriasis cases and is characterized by well delineated reddish and scaly papules and 
plaques, typically on the elbows, knees and scalp or in other cutaneous surfaces. 
Psoriatic skin changes have been described since biblical times. The first documented 
description is found in the Old Testament in the third book of Moses. It was confused with 
leprosy for hundred of years, and, therefore, many people with psoriasis was ostracised in 
the Middle Age. At the beginning of the 19th century, Robert Willan, an English physician, 
was the first to clinically describe psoriasis (Crissey and Parish 1998). Humankind suffered 
and studied this disease for at least 3000 years, and, naturally, several possible causes for the 
disease have been hypothesized. 
Nowadays it is accepted that psoriasis is a chronic, recurrent, immune-mediated 
inflammatory disease, with a recognised genetic predisposition. The primary immune defect 
appears to be an increase in cell signalling via chemokines and cytokines that act up-
regulating gene expression, causing keratinocyte hyperproliferation. T lymphocytes and 
their cytokines and chemokines appear to be the driver of lesion development and 
persistence, although other cells, such as endothelial cells, dendritic cells, neutrophils and 
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keratinocytes play also an important role, along with other cytokines and growth factors 
(Chen, de Groot et al.; Wollenberg, Wagner et al. 2002; Sano, Chan et al. 2005). Currently, it 
is proposed that psoriasis development depends on skin infiltration of T helper (Th)1/Th17 
cells that stimulate macrophages and dermal dendritic cells to release mediators that sustain 
inflammation and cause abnormal keratinocyte proliferation. Interleukin (IL)-23 has the 
potential to activate Th17 cells, stimulating their survival and proliferation and serving as a 
key master cytokine regulator in psoriasis (Blauvelt 2008). Th17 cells secrete IL-17, IL-21 and 
IL-22, with the latter mediating IL-23 induced acanthosis and dermal inflammation (Zheng, 
Danilenko et al. 2007; Kunz 2009).Therefore, the IL-23/Th17 axis seem to play an important 
role in psoriasis and explains the hyperplasia of psoriatic keratinocytes (by IL-22), and why 
neutrophils appear in a chronic inflammatory disease, such as psoriasis (IL-8 production 
induced by IL-17) (Di Cesare, Di Meglio et al. 2009). More recently, functional interactions 
between IL-33 and mast cells were also found to contribute to inflammatory conditions, 
such as psoriasis (Xu, Jiang et al. 2008; Castellani, Kempuraj et al. 2009; Theoharides, Zhang 
et al. 2010). Nonetheless, the immunologic target molecule that would allow to classify 
psoriasis as an autoimmune disease, as well as, the events that trigger the inflammatory 
process, remain to be determined. 
Patients with psoriasis require an individual management and long-term planning of 
therapeutic strategies. The ratio risk versus benefit, and the cost-effectiveness of the different 
treatments should be carefully evaluated. The therapy is chosen in accordance with skin type, 
clinical history, patient’s age, severity of psoriasis and the response to previous treatments. 
Topical agents are, usually, chosen for milder forms and limited psoriasis; phototherapy, 
photochemotherapy and systemic agents for moderate and severe psoriasis. Biological 
therapies, the more recent therapies for psoriasis, are particularly used for severe psoriasis.  
2. Epidemiology  
Psoriasis affects about 125 million of people worldwide (National Psoriasis Foundation), is 
common in Caucasians and affects equally men and women. The prevalence of psoriasis in 
the population of Northern Europe and Scandinavia is 1.5-3%. While relatively common in 
Japanese, it is less common in Chinese, Eskimos, West Africans and North American blacks, 
and very uncommon in North American and South American natives and aboriginal 
Australians (Langley, Krueger et al. 2005). The causes for these variations are likely to be 
genetical and environmental; actually, population-based and twin studies indicate psoriasis 
as an heritable disease with a polygenic mode of inheritance, with variable penetrance 
(Elder, Nair et al. 1994). The prevalence of psoriasis seems to be affected by latitude 
(Vazquez, Carrera et al. 2006).  
The onset of psoriasis can be at any time of life and, afterwards, it usually persists for life. 
The mean age of onset of psoriasis vulgaris is at 33 years, and 75% of the patients develop 
psoriasis before 46 years of age (Nevitt and Hutchinson 1996). It has been also suggested 
that psoriasis onset is bimodal, with a peak at 16- 22 and the other peak at 57-60 years of age. 
The age of onset is slightly earlier in women than in men.  
Psoriasis is a relapsing disease, although natural remission occurs in about one-third of the 
psoriatic patients (Farber and Nall 1974). 
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According to Henseler and Christophers (Henseler and Christophers 1985) there are two 
types of psoriasis, defined by the age of psoriasis onset: type I, when it occurs at or before 40 
years of age, and type II, when it occurs after the age of 40 years. Type I disease accounts for 
more than 75% of the cases. These patients are much more likely to express susceptibility 
alleles at the human leukocyte antigen (HLA) loci, to have affected first-degree relatives and 
to experience a more severe and recurrent disease than patients with type II psoriasis.  
The course and progress of psoriasis is apparently unpredictable. 
3. Clinical features  
Psoriasis vulgaris or chronic plaque psoriasis, is the classic and the most common form of 
psoriasis presentation. The other forms of psoriasis include guttate, erythrodermic and 
pustular psoriasis. It is characterized by papulosquamous plaques well-defined from 
surrounding normal skin (Figure 1A). These plaques are red or salmon pink, covered by 
white or silvery scales, and the plaques may be thick, thin, large or small. They are more 
active at the edge and are, usually, symmetrically distributed, occurring commonly on 
elbows, knees, scalp, lumbosacral region and umbilicus. 
Psoriasis vulgaris may have a variable course, presenting chronic stable lesions or plaques 
with a rapid onset and widespread involvement. It is, usually, symptomatic, with patients 
complaining of intense pruritus or burning; about 30% of the patients suffer from itch and 
pain, mostly due to the dryness and cracking of the psoriatic area.  
Early lesions frequently start as small pinpoint papules, which, soon in their evolution, 
show scaling. The amount of scaling varies among patients, and at different body areas on a 
given patient, and its removal may reveal tiny bleeding points (Auspitz sign) (Murphy, Kerr 
et al. 2007). A white blanching ring, known as Woronoff`s ring may be observed in the skin 
surrounding a psoriatic plaque. 
In inactive disease, the few existing plaques remain with the same size, and new ones do not 
appear. 
Worsening of the disease is associated with enlargement of existing lesions and appearance 
of new, small lesions. With gradual peripheral extension, the plaques may develop different 
configurations: in psoriasis gyrata, a curved linear pattern predominates; in annular 
psoriasis, ring-like lesions develop secondary to central clearing; and in psoriasis follicularis, 
minute scaly papules are present at the opening of the pilosebaceous follicles (Langley, 
Krueger et al. 2005). The terms rupioid and ostraceous are related to distinct morphological 
subtypes of plaque psoriasis. Rupioid plaques are small and highly hyperkeratotic, 
resembling limpet shells. Ostraceous psoriasis refers to hyperkeratotic plaques, with 
concave centres, similar in shape to oyster shells (Langley, Krueger et al. 2005).  
Site-specific variants of psoriasis vulgaris exist. Flexural or inverse psoriasis occurs in 
intertriginous sites. Seborrhoeic psoriasis occurs in eyebrows, nasolabial folds, 
postauricular and presternal sites. Psoriatic nail disease is most commonly found in 
patients with psoriatic arthritis. Fingernails are more commonly affected than toenails, 
and the clinical manifestations range from pitting, yellowish discoloration, and 
paronychia, to subungual hyperkeratosis, onycholysis, and severe onychodystrophy 
(Salomon, Szepietowski et al. 2003). 
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Fig. 1. Psoriasis clinical manifestations: A - chronic plaque psoriasis, B - guttate psoriasis, C - 
pustular psoriasis, D - erythrodermic psoriasis (With permission of Américo Figueiredo, 
PhDMD, and of Hugo Oliveira, MD). 
Psoriatic arthritis is a seronegative inflammatory arthritis that occurs in the presence of 
psoriasis vulgaris. Five types of this psoriasis have been proposed: distal interphalangeal 
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joint only, asymmetrical oligoarthritis, polyarthritis, spondylitis and arthritis mutilans 
(Wright 1956; Wright 1959a; Wright 1959b). Gladman expanded the five sub-groups to 
seven: distal disease, oligoarthritis (<4 joints), polyarthritis, spondylitis only, distal disease 
plus spondylitis, oligoarthritis plus spondylitis and polyarthritis plus spondylitis (Gladman, 
Shuckett et al. 1987). About 10-30% of patients with psoriasis vulgaris develop psoriatic 
arthritis. It is controversial whether or not the skin condition and arthritis represent a 
different manifestation of the same disease. Immunological studies, genetic evidence and 
different responses to treatment, suggest that they might be different conditions with a 
similar underlying inflammatory process (Pitzalis, Cauli et al. 1996; Ho, Bruce et al. 2005). 
Psoriasis vulgaris can be classified in accordance with the configuration of the lesions and 
their localization. It is also classified, according to the severity of clinical presentation, in 
mild, moderate and severe (see Assessing psoriasis severity). 
Guttate psoriasis (Figure 1B), an acute form of psoriasis that develops especially in children, 
adolescents and young adults, is characterized by papules with less than 1 cm in diameter 
that erupt in the trunk and extremities, about 2 weeks after a -haemolytic streptococcal or a 
viral infection, and/or after acute stressful life events. Usually, it is self-limited, resolving in 
3-4 months, however its long-term prognosis is unknown. Some affected individuals may 
progress to a chronic form of plaque psoriasis and sparkles of guttate lesions may appear 
during the course of chronic plaque psoriasis (Martin, Chalmers et al. 1996). 
Pustular psoriasis (Figure 1C) is an acute form of psoriasis, in which small, monomorphic, 
sterile pustules develop in painful inflamed skin. It can be generalized and potentially life-
threatening or it can be localized, presenting as palmoplantar pustulosis or acrodermatitis 
continua of Hallopeau. Acrodermatitis continua is a rare, chronic, pustular eruption of the 
fingers and toes. Palmoplantar pustulosis is characterized by hyperkeratosis and clusters of 
pustules over the hands and/or feet; some authors claim, however, that this form is not 
really a psoriasis form (Asumalahti, Ameen et al. 2003). Patients with generalized pustular 
psoriasis may have pre-existing plaque psoriasis or develop it after pustular episodes. An 
intercurrent infection, or the abrupt withdrawal of systemic and, occasionally, of ultrapotent 
topical corticosteroids may also trigger this form of psoriasis. 
In erythrodermic psoriasis (Figure 1D), more than 90% of the skin surface area is affected, 
which may lead to hypothermia, due to an impairment in the thermoregulation of the 
skin, high output cardiac failure, infection and metabolic changes. These changes include 
hypoalbuminaemia and anaemia due to loss of iron, vitamin B12 and folate. This form of 
psoriasis can be a life-threatening condition. It may present as chronic plaque psoriasis 
that gradually worsens, as plaques become confluent and extensive. Erythroderma may 
also be precipated by infection, tar, drugs, or withdrawal of corticosteroids (Langley, 
Krueger et al. 2005). 
4. Genetic predisposition  
A genetic predisposition to develop the disease appears to exist. Indeed, psoriasis develops 
in bone marrow transplant recipients from donors with psoriasis, and clears in recipients 
from donors without psoriasis (Wahie, Alexandroff et al. 2006). 
About 30% of psoriatic patients present a family history of the disease in a first or second-
degree relative. In fact, the probability to develop psoriasis is raised when first-grade relatives 
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suffer from the disease. The risk to develop psoriasis appears to be about 20% if one parent has 
psoriasis and about 75% if both parents are affected (Watson, Cann et al. 1972).  
Psoriasis has been associated with certain HLA-types (HLA-Cw6, HLA-B13, HLA-B17, 
HLABw57, HLA-DR4), and those with HLA-Cw6 seem to have a 10-fold higher risk to 
develop the disease. A collaborative genome-wide association study of psoriasis involving 
thousands of cases and controls revealed association between psoriasis and seven genetic 
loci: HLA-C, IL12B, IL23R, IL23A, IL4/IL13, TNFAIP3, and TNIP1 (Elder, Bruce et al. 2010). 
Moreover, a family history of psoriasis, an early-onset of the disease and the presence of 
HLA-Cw*0602 (the major determinant of phenotypic expression), have been associated to a 
more unstable and severe clinical course, as compared to those patients with late onset 
psoriasis and negative for HLA-Cw*0602 (Henseler and Christophers 1985; Gudjonsson, 
Karason et al. 2006).  
The molecular genetic basis of psoriasis is complex, with evidence that multiple genes are 
involved. At least nine chromosomal susceptibility loci have been revealed (PSORS1-9). The 
PSORS1 gene, in the major histocompatibility complex region on chromosome 6 (6p21), 
appears to be associated with most cases of psoriasis. However, the exact location of 
PSORS1 gene remains controversial. Furthermore, the penetrance of PSORS1 locus is 
estimated to be less than 15%, implying that other genetic and/or environmental factors 
may also contribute to the liability of the disease. Moreover, an association of PSORS with 
functional polymorphisms in modifier genes that mediate inflammation (e.g., tumour 
necrosis factor (TNF)-α) and vascular growth (e.g., vascular endothelial growth factor), has 
been found (Capon, Munro et al. 2002).  
Thus, whereas the existence of a genetic component in psoriasis is certain, the exact location 
of the genes involved remains to be determined.  
Psoriatic patients present a substantial genetic heterogeneity and it is likely that this genetic 
heterogeneity could lead to subtle differences in disease pathogenesis, explaining the 
different responses to treatment observed in the patients.  
5. Triggering factors  
Psoriasis has a complex genetic predisposition, with a complex inheritance pattern, plus an 
environmental component. The development and exacerbation of psoriasis appears to 
involve an interaction between multiple genetic and environmental risk factors. Usually, 
psoriasis is triggered by infection, inflammation, stress, skin injury and drugs.  
Several microbial infections are associated with the development and/or worsening of 
psoriasis. A strong association is the induction of guttate psoriasis by a preceding tonsilar 
Streptococcus pyogenes infection. Disease exacerbation has been associated with skin and/or 
gut colonization by Staphylococcus aureus, Malassezia and Candida albicans (Noah 1990; 
Waldman, Gilhar et al. 2001). Streptococcal infections precede the development or 
worsening of psoriasis in more than 90% of patients with type I psoriasis (Weisenseel, 
Laumbacher et al. 2002). The role, if any, of viruses (papilomaviruses, retroviruses, 
endogenous retroviruses) present in lesional skin is unknown. 
In about 30% of patients, the lesions appear at sites of skin injury - the Koebner 
phenomenon (Holzmann, Werner et al. 1992). This phenomenon is an indicator of disease 
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activity and may have a prognostic value, as it is, usually, associated with early onset of 
psoriasis. Interestingly, light-induced psoriasis, resulting from an excessive sun exposure 
(that may improve psoriasis if used appropriately), is also a form of Koebner phenomenon. 
There is a growing list of drugs that may aggravate existing psoriasis or induce it for the 
first time. The frequency of this adverse event varies between drugs. The most commonly 
proposed causative agents are -blockers, lithium, synthetic anti-malarial drugs, non-
steroidal anti-inflammatory drugs, angiotensin-converting enzyme inhibitors and 
tetracycline antibiotics (Wolf, Lo Schiavo et al. 1997; O'Brien and Koo 2006).  
Evidences confirm that the onset of plaque psoriasis is highly associated with a preceding 
stressful life event (Mallbris, Larsson et al. 2005); indeed, chronic psychological stress may 
influence the development of psoriasis and affect its clinical expression (Naldi, Chatenoud 
et al. 2005). 
Diet is sometimes referred as a possible triggering factor for psoriasis, but no consistent data 
exist. Apparently, fish oil diet or a diet consisting predominantly of glucose and unsaturated 
fatty acids has beneficial effects on psoriasis (Lithell, Bruce et al. 1983; Caspary, Elliott et al. 2005). 
Alcoholism, cigarette smoking, obesity, type 2 diabetes mellitus, and metabolic syndrome 
increase the risk for developing psoriasis (Naldi, Chatenoud et al. 2005; Neimann, Shin et al. 
2006). These factors may influence clinical severity and prognosis of psoriasis and, as risk 
factors for cardiovascular diseases (CVD), may underlie the increased morbidity and 
mortality for CVD events observed in psoriatic patients.  
Some authors stated (Mallbris, Larsson et al. 2005; Naldi, Chatenoud et al. 2005) that obesity 
precedes and may represent a risk factor to develop psoriasis. Moreover, after the onset of 
psoriasis, obesity seems to contribute to its exacerbation (Sterry, Strober et al. 2007). We found 
(Coimbra, Oliveira et al. 2010a) that the prevalence of overweight/obesity in psoriatic patients 
is high, with overweight/obese patients presenting higher leptin, resistin, TNF-α and IL-6 
levels, and lower adiponectin values, as compared to patients with a normal body mass index. 
Obesity itself, by increasing friction and trauma in the waistline and intertriginous areas, may 
worsen psoriasis by the Koebner phenomenon (Higa-Sansone, Szomstein et al. 2004). 
Furthermore, obesity may favour the onset of the disease, by providing a chronic level of low-
grade inflammation that may contribute to trigger the development of psoriasis and may 
account for its severity (Hamminga, van der Lely et al. 2006).  
Indeed, inflammation seems to be a central key in psoriasis onset and exacerbation. Studies 
in our lab (Coimbra, Oliveira et al. 2010b; Coimbra, Oliveira et al. 2010c) showed that 
worsening of psoriasis is linked to an enhanced inflammatory response with neutrophil 
activation and in which the cytokine network is disturbed. We also found that after a 
successful treatment the inflammatory markers levels decreased. Nonetheless, at clearing of 
the disease, a residual inflammatory response still persists, what may be important for the 
relapse episodes that are characteristic of psoriasis. 
6. Psoriasis vulgaris histological features  
Psoriasis presents three main histological features: epidermal hyperplasia (acanthosis), 
dilated and prominent blood vessels in the dermis, and an inflammatory infiltrate of 
leukocytes, predominantly in the dermis (Gonzalez, Rajadhyaksha et al. 1999; Werner, 
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Bresch et al. 2008). The histopathological findings in psoriasis lesions, however, may vary as 
a consequence of the recurrent courses of exacerbation of the disease. The increase in 
epidermal proliferation and in inflammation are not uniform, even within the same lesion of 
chronic plaque type psoriasis. Typically, they are higher at the centre of the pinpoint of early 
lesions, whereas in more developed plaque lesions these changes are found at the border. 
A sparse superficial perivascular T-lymphocytic infiltrate of the dermis is, usually, the 
earliest alteration observed in the lesions. This is followed by the development of dilated 
and tortuous blood vessels within dermal papillae, by mild dermal oedema, and by minimal 
spongiosis, with rare T-lymphocyte and/or neutrophil exocytosis. Subsequently, a slight 
epidermal hyperplasia, with higher neutrophil exocytosis and small mounds of 
parakeratosis (retention of nuclei in cells of the stratum corneum) containing neutrophils are 
observed. The infiltrate in the dermis at this early plaque stage is, usually, composed of 
lymphocytes, histiocytes and neutrophils, in addition to red blood cells.  
The developed plaques show marked epidermal hyperplasia, with regular elongation of 
epidermal rete ridges with characteristic bulbous enlargement of their tips; elongation of 
intervening dermal papillae containing dilated and tortuous capillaries; fine fibrillary collagen 
and thinning of epidermis that lies immediately above the dermal papillae. Additionally, there 
is pallor of the superficial layers of the epidermis and spongiosois is minimal or absent. There 
is marked hyperkeratosis, as well as, hypogranulosis subjacent to areas of parakeratosis. In 
most cases, neutrophils within the parakeratosis are present (Munro’s microabscesses). 
Spongiform pustules of Kojog may be formed, due to the migration of neutrophils from the 
papillary capillaries that aggregate beneath the stratum corneum and in the upper Malpighian 
layer between degenerating and thinned keratinocytes (Mehta, Singal et al. 2009). 
Subsequently, the keratynocytes at the centre of the pustule degenerate, with formation of a 
large single cavity surrounded by thinned keratinocytes.  
Both T cell subsets, CD4+ and CD8+ T cells, are present in early stage and developed 
lesions, but, whereas CD8+ T cells are preferentially present within the epidermis (Bos, 
Hagenaars et al. 1989), CD4+ T cells are mainly in the dermis. Currently, it is also believed 
that a separate population of T-helper (Th) cells beside the Th1 cells, namely, the Th17 cells, 
are present at psoriatic lesions (Lowes, Kikuchi et al. 2008). 
The characteristic massive scaling is a consequence of a thickened, irregular stratum 
corneum with parakeratosis and epidermal thickening with acanthosis, papillomatosis, and 
absence of granular layer. Epidermal thickening is caused by increased keratinocyte 
proliferation, reflecting the increased mitotic activity within the basal and suprabasal layers. 
In normal skin, the maturation of keratinocytes from the basal layer to the cornified layer 
takes about 28 days, whereas in the psoriatic lesion, it is shortened to 5 days. This shortened 
maturation is associated with massively disrupted terminal differentiation of keratinocytes 
and is mainly reflected by parakeratosis. 
As referred, the psoriatic plaque is characterized by profound histological disturbances and 
by the presence of different and unusual cell types. There is a marked infiltration of 
mononuclear leukocytes, the development of elongated/hyperplastic blood vessels in the 
papillary dermal region that accounts for the visible redness of psoriatic skin lesions. At the 
early stage of the plaque, infiltration of T cells, dendritic cells and monocytes/macrophages 
occurs. Later, the cellular density of these infiltrates increases, and infiltrates of CD8+ T cells 
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and neutrophilic granulocytes occur, particularly in the epidermis. Many lymphocytes, 
monocytes, and neutrophils are clearly adherent to endothelial cells.  
Leukocytes can gain skin parenchyma by transmigration through reactive blood vessels, 
and resident skin leukocytes might increase creating the dense infiltrates, observed in 
psoriatic lesions. Although Langerhans cells and dermal dendritic cells have long been 
recognized as the main types of dendritic cells in skin, only more recently the types of 
dendritic cells in psoriatic lesions were identified, such as, CD11c+ (myeloid) and 
plasmocytoid dendritic cells. CD11c+ dendritic cells correspond to interstitial dendritic cells 
in other tissues and are the most abundant dendritic cell type in the dermis (Lowes, 
Chamian et al. 2005; Nestle, Conrad et al. 2005). 
Polymorphonuclear neutrophils seem to play a pivotal role in the acute inflammatory 
changes of psoriatic lesions. Areas of parakeratosis appear to contain abundant neutrophils 
(Cox and Watson 1972). In addition, it is known that pronounced parakeratosis is associated 
with the presence of neutrophils and that Munro’s microabscesses are located exclusively 
within areas of parakeratosis (van de Kerkhof and Lammers 1987). Coexistence of 
neutrophils and parakeratosis is in part explained by the tissue destructive properties of 
active oxygen intermediates and proteolytic enzymes that are released by activated 
neutrophils attached to the stratum corneum (Terui, Ozawa et al. 2000).  
It is of interest, the fact that resolving or treated plaques of psoriasis show initially a 
progressive reduction of neutrophils within the stratum corneum and of the parakeratosis, 
with regeneration of the granular zone. The epidermal changes resolve later. The 
histopathologic clue of the disease that may remain is a residual mild superficial dermal 
fibrosis with persistence of papillary dermal capillary dilatation and tortuosity (Murphy, 
Kerr et al. 2007).  
In summary, histologically, in psoriasis, there is marked acanthosis, accompanied by 
parakeratosis and a mixed dermal infiltrate, including CD4+ T cells, dendritic cells, 
macrophages, and mast cells. Indeed, by immunostaining for IL-17A and IL-22, it has been 
shown numerous cells present in the psoriasis lesions which are able to produce these 
cytokines (Harper, Guo et al. 2009). In the epidermis, neutrophilic exudates and CD8+ T 
cells are often seen. Dermal papillary blood vessels are dilated and tortuous. 
7. Assessing psoriasis severity  
In clinical practice, broad global assessments of psoriasis activity and its effect on patient’s 
quality of life are used to define the severity of patient’s disease and to define the more 
appropriate treatment. Furthermore, in clinical trials, the quantification of the disease 
severity is critical to measure the efficacy of the treatment under study, by comparing the 
severity of disease before and after the treatment. 
The severity of psoriasis can be defined by the percentage of body surface area involved. In 
mild cases, the lesions cover less than 10% of the body surface, in moderate cases 10-20% and 
in the severe cases the lesions affect more than 20% of skin surface (Naldi and Gambini 2007). 
There are several other approaches to measure the severity of psoriasis, which consider not 
only the affected skin surface, but also the degree of scaling and the type of infiltration.  
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The Psoriasis Area and Severity Index (PASI) is the prototype for such measures, and is the 
most widely used tool to assess psoriasis severity in clinical trials and in clinical practice. It 
was developed as an outcome measure in clinical trials on oral retinoids in 1978 
(Frederiksson T 1978). 
The PASI score ranges from 0 to 72. It combines the assessment of four body areas: head and 
neck, upper limbs, trunk and lower limbs. To assess affected body surface area, the 
proportion of skin affected in each area is given by a numerical score, representing the 
proportion involved. Within each area the severity of the lesions is assessed by three signs, 
erythema, thickness/induration, and desquamation/scaling; each of the three signs is 
assessed on a five-point scale. Finally, the PASI score is calculated according to an 
appropriate formula (Figure 2).  
 
Fig. 2. Psoriasis Area and Severity Index (PASI) score assessment (H, head; LL, lower limbs; 
T, trunk; UL, upper limbs). 
A PASI score below 10 defines psoriasis as mild, between 10 and 20 as moderate, and above 
20 as severe (Naldi and Gambini 2007). The evaluation of PASI presents some subjectivity, 
which is reduced when patients are evaluated always by the same dermatologist. 
The PASI system has two major advantages: it is sensitive to changes in the area of the 
affected skin and in the severity of the lesions; therefore, the changes in PASI score reflect 
improvement or worsening of the disease. Its widespread use in the research setting means 
that it is possible to compare information from different studies. When conducting a clinical 
trial for treatment of psoriasis, a predetermined endpoint is required, on which the efficacy 
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of the drug will be assessed. It is established that a 75% improvement in PASI, defined as 
PASI 75, is a clinically meaningful endpoint for clinical trials, and there is strong evidence 
demonstrating that 50% improvement in PASI (PASI 50) could also be a clinically 
meaningful endpoint (Carlin, Feldman et al. 2004). A major limitation of the PASI is that it is 
not routinely used by clinicians and, therefore, is poorly understood by both clinicians and 
patients. It also presents poor sensitivity to changes in small areas of involvement. 
Therefore, PASI is not the best tool to be used in patients with mild disease.  
Another traditional assessment tool to evaluate psoriasis severity is the Physician’s Global 
Assessment (PGA), a simple instrument that provides a subjective global evaluation. There 
are several variants for PGA. Typically, the patient is asked to rate the disease, using a scale 
of seven categories, “clear”, “almost clear”, “mild”, “mild to moderate”, “moderate”, 
“moderate to severe” and “severe”. It is less objective than PASI, but the result is more 
easily understood by the patient (Berth-Jones, Grotzinger et al. 2006).  
The Lattice System Physician’s Global Assessment (LS-PGA), formerly known as Lattice System 
Global Psoriasis Scale, applies a more objective approach to global assessment of disease 
severity than PGA, because it considers the body surface area involved and the morphological 
characteristics of the plaques (Berth-Jones, Grotzinger et al. 2006). Total body surface area 
involved is estimated using a scale of seven categories (0, 1-3, 4-9, 10-20, 21-29, 30-50,  51%). 
Then, using a matrix system, the average of plaque characteristics (elevation, erythema and 
scaling) will be evaluated. The categories, on an eight-point scale, are: “clear”, “almost clear”, 
“mild”, “mild to moderate”, “moderate”, “moderate to severe”, “severe”, and “very severe”. 
Despite the importance of the evaluation of psoriasis severity, there is a lack of consensus on 
the most appropriate measures (van de Kerkhof 1997; Chalmers and Griffiths 2003; Langley 
and Ellis 2004), though PASI, PGA, and LS-PGA appear to be highly correlated with each 
other (Langley and Ellis 2004). Despite the referred limitations, the PASI score is the most 
accepted and widely used measure in clinical trials and in clinical practice (Ashcroft, Wan 
Po et al. 1999).  
Other important psoriasis measurement tools are under development, especially those that 
also measure the patient's perception of well-being. The National Psoriasis Foundation has 
developed the National Psoriasis Foundation Psoriasis Score, a responder index, that include 
six subdomains: induration at two target sites, current and baseline body surface area, 
physician global assessment, patient global assessment, and patient assessment of itch 
(Gottlieb, Chaudhari et al. 2003). 
Two other quantitative ways of measuring psoriasis are biopsies and photographs. Biopsies 
are attractive because they are objective, however, their major limitation is that psoriasis 
does not resolve in a uniform way, and, therefore, biopsies may not provide a representative 
sampling of lesions. In theory, photographs could be used to confirm real time assessments 
of disease severity. It is not clear, however, if thickness/induration or even scaliness of 
lesions can be accurately assessed using the photographs. Nevertheless, photographs do 
make a strong impact in educating physicians and, therefore, they are commonly 
incorporated into clinical  trials.  
Most of these tools do not include a measure about the quality-of-life or considers the 
patient's perception of well-being. Thus, any direct information about psychological and/or 
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social disease consequences is not provided. Indeed, a major component in the assessment 
of psoriasis should be the measurement of the quality of life, because the improvement in 
patients’ lives is the primary goal of therapy. The term quality of life, or health related 
quality of life (HRQOL), refers to a quantitative estimation of the global impact of a disease 
on physical, social, and psychological well-being of a patient. It appears that there is not 
always a strong correlation between the HRQOL and the severity of the disease, as defined 
by PASI. For instance, the visibility of psoriatic lesions or the impairment of daily activities 
may incapacitate a patient to work; itch and pain may cause severe impairment of HRQOL.  
The estimation of quality of life is obtained through standardized questionnaires exploring 
the relevant dimensions of the patient’s life that may be affected by the disease. Non-specific 
queries, such as the Medical Outcome Survey Short Form 36 (SF-36) and  the Euro QOL, are 
used to assess patients’ overall quality of life (Ware and Sherbourne 1992; Brazier, Jones et 
al. 1993).  
There are more specific instruments, focusing on aspects of quality of life that are affected by 
skin disease. These, include the Dermatology Life Quality Index (DLQI) and the Skindex 
(Finlay and Khan 1994; Chren, Lasek et al. 1997). There are even more specific measures for 
psoriasis. For instance, scores that include psychological impact along with the severity of 
the skin lesions are the Salford Psoriasis Index and the Psoriasis Disability Index (Kirby, 
Fortune et al. 2000). A psoriasis-specific study of QOL, the PSORIQOL, is a recently 
introduced 25-item instrument (McKenna, Cook et al. 2003).  
The DLQI and the SF-36 have been previously used to evaluate the HRQOL on psoriatic 
patients (Feldman, Gottlieb et al. 2008; Reich and Griffiths 2008). The generic queries, such as 
the SF-36, are useful to show the impact of psoriasis. The SF-36 has showed that the impact of 
psoriasis was similar or higher than that imposed by many other serious medical conditions.  
The DLQI has been most widely used in psoriasis trials as a measure to assess the quality of 
life related to skin disease. Indeed, it has been used in more than 35 psoriasis studies, and it 
has been used very extensively over the last years in the study of the new generation of 
systemic therapies for psoriasis. Furthermore, it has been shown that the value of clinical 
research in psoriasis is improved in the DLQI, as the DLQI score banding proposes: 0-1 
means “no effect on QOL”; 2-5, “small effect”; 6-10, “moderate effect”; 11-20, “very large 
effect”; 21-30, “extremely large effect”. Apparently, a total DLQI higher than 10 represents a 
skin disease having a very large effect on patient’s life, needing intervention, and, from the 
individual point of view, a DLQI of 5 or less is associated with improved QOL.  
Quality of life clarified the multidimensional nature of disease assessment and outcome, 
which should include the evaluation of disease associated discomfort, level of disability, and 
social disruption. It is important to define the severity of psoriasis, but it is also important to 
identify psoriasis that severely affects the quality of life. 
8. Psoriasis psychosocial aspects  
A number of psychiatric/psychological comorbidities have been observed in psoriatic 
patients. Psoriasis deeply affects the well-being of the patient and has emotional and social 
consequences (Jobling and Naldi 2006). Thus, to define psoriasis as only a skin problem is a 
very restrictive approach.  
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Psoriatic patients present a variety of psychological problems, including poor self esteem, 
sexual dysfunction, anxiety and depression. Indeed, about 35% of psoriatic patients report 
symptoms of depression (Friedewald, Cather et al. 2008); about 80% of patients refer that the 
disease has a negative impact on their lives for a variety of reasons, including the physical 
symptoms, upsetting physical appearance (particularly because its onset is before 30 years 
of age in 60% of the cases), frustration, anger, anxiety, depression, and increased use of 
alcohol (Mease and Menter 2006). Since psoriasis is a persistent, disfiguring and 
stigmatizing disease, clinicians need to be aware of the emotional and psychological impact 
of psoriasis in the patient.  
Major depression seems to be a significant predictor of CVD events. It may be an 
independent risk factor for death, after suffering an acute myocardial infarction (Carney, 
Blumenthal et al. 2003), and it may increase the risk for coronary artery disease (Barth, 
Schumacher et al. 2004). An association between depressive symptoms and the levels of 
serum inflammatory markers was also reported (Stewart, Janicki-Deverts et al. 2008). Acute 
or chronic psychological stress, may induce a chronic inflammatory process that may 
culminate in atherosclerosis (Black and Garbutt 2002). 
It is known that in psoriatic patients, psychological stress, by itself, can play a role in 
exacerbation of psoriasis, and that higher stress reactivity has been associated with the onset 
of psoriasis at an earlier age (Naldi, Chatenoud et al. 2005). Indeed, 31% of the patients 
reported the onset of psoriasis in periods of increased everyday life stress, and in 71% of 
patients, psoriasis symptomatology worsened during stressful life episodes (Griffiths and 
Richards 2001; Zachariae, Zachariae et al. 2004). The importance of stress in psoriasis has 
been further highlighted, since psychological distress affects treatment outcome in psoriatic 
patients. For instance, the level of stress may prolong the time taken for psoralen plus UVA 
(PUVA) to clear the symptoms of psoriasis (Fortune, Richards et al. 2003). Accordingly, 
stress reduction by stress management, relaxation or cognitive techniques shortened the 
time to clear psoriasis symptoms by PUVA, and, moreover, improved the clinical severity of 
psoriasis (Kabat-Zinn, Wheeler et al. 1998; Fortune, Richards et al. 2002). An interesting 
finding is the increase in the catecholamine levels after stress exposure in psoriatic patients 
(Buske-Kirschbaum, Ebrecht et al. 2006), pointing to a hyper responsive sympatho-
adrenomedullary system in psoriasis.  
The relevance of stress in psoriasis is broadly accepted, however, the underlying 
mechanisms, of how psychological distress exacerbates or triggers psoriasis, are poorly 
understood. It is known that psychological stress has the potential to regulate the immune 
response, and there is emerging evidence that abnormal neuroendocrine response to stress 
may contribute to the pathogenesis of chronic autoimmune diseases (Jorgensen, Bressot et 
al. 1995). 
Psoriatic patients often manifest not only a profound psychosocial disability, but also a 
significant impairment of health related quality of life (Reich and Griffiths 2008). The lack of 
understanding by the family members may increase the level of anxiety in the patient; the 
QOL of relatives and partners of patients with psoriasis can also be significantly affected 
(Eghlileb, Davies et al. 2007).  
Some authors believe that HRQOL is more determined by how an individual mentally 
copes with the disease than by the amount of skin affected (Stern, Nijsten et al. 2004; 
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Friedewald, Cather et al. 2008). Others, refer that the impact of the disease in HRQOL seem 
to be greater in patients with more extensive skin involvement (Gelfand, Feldman et al. 
2004). Thus, clinicians need to try to perceive the severity of psoriasis from the patient’s 
point of view. From the patient’s perspective, psoriasis is usually considered as severe, if it 
causes embarrassment or anxiety, pruritus or soreness; if it affects relationships, everyday 
activities, working, studying or sport activities, or if there is joint involvement. In a survey 
of patients with severe forms of psoriasis, 79% reported that psoriasis had a negative impact 
on their lives, 40% felt frustration with recurrent treatments, and 32% did not perceive their 
treatment to be sufficiently aggressive (Krueger, Koo et al. 2001). The impact of psoriasis 
seems to be more severe for young adults (18-24 years old), particularly, for women, singles, 
patients with visible psoriasis, patients who developed psoriasis in early childhood, patients 
who have a negative state of mind as a result of psoriasis, or patients who have experienced 
additional problems due to psoriasis (Young 2005). 
It is known that the stress caused by living with psoriasis can be manifested as avoidance 
behaviours. Active psoriasis seems to lead to a marked loss of productivity (Fowler, Duh et 
al. 2008). In fact, the two main contributors to stress in patients with psoriasis are engaging 
in avoidance behaviour and the belief that they are being evaluated on the basis of their skin 
disease, which may lead to low grade persistent stress. It has been reported that psoriatic 
patients present a reduction in physical and mental functioning comparable to that observed 
in patients with cancer, arthritis, hypertension, heart disease and depression (Rapp, 
Feldman et al. 1999). Furthermore, the general health status of the patient may be affected 
by all the diseases that associate with psoriasis, creating a substantial impact on HRQOL.  
Psychological sequelae of the disease can impair the response to treatment, since patients 
with pathological levels of anxiety are less likely to respond to therapy (Fortune, Richards et 
al. 2003). Thus, stress in the form of pathological worry has a deleterious effect on response 
to therapy. In consequence, psychological intervention may play an important role in the 
management of psoriasis patients. 
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